A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis

Trial Profile

A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms ACT-1
  • Sponsors Centocor; Janssen Biotech
  • Most Recent Events

    • 12 Jun 2018 Results of individual participant data (IPD) pooled analysis of five trials of infliximab and golimumab in UC, to evaluate whether concomitant use of 5-Aminosalicylates modifies clinical outcomes, were published in the American Journal of Gastroenterology.
    • 05 Jun 2018 Results of a pooled analysis of ACCENT-I, SONIC, ACT-1, and ACT-2 (n=1205) assessing the association between obesity and response to infliximab, published in the American Journal of Gastroenterology
    • 30 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top